Bellus Health

YTD

ALL

Why Robinhood?

You can watch Bellus Health and buy or sell other stocks, ETFs, and their options commission-free!

About BLU

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch.

CEO

Roberto Bellini

CEORoberto Bellini

Employees

—

Employees—

Headquarters

Laval, Québec

HeadquartersLaval, Québec

Founded

1993

Founded1993

Employees

—

Employees—

BLU Key Statistics

Market cap

1.87B

Market cap1.87B

Price-Earnings ratio

-20.45

Price-Earnings ratio-20.45

Dividend yield

—

Dividend yield—

Average volume

4.95M

Average volume4.95M

High today

—

High today—

Low today

—

Low today—

Open price

—

Open price—

Volume

0.00

Volume0.00

52 Week high

$14.76

52 Week high$14.76

52 Week low

$6.38

52 Week low$6.38

People also own

Based on the portfolios of people who own BLU. This list is generated using Robinhood data, and it’s not a recommendation.